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INTRODUCTION
The 21st century may come to be known as the Age of
Biotechnology in much the same way that the end of the 20th century
became known as the Information Age. However, while innovations
in the field of biotechnology have great potential, biotechnology
1
carries high business risk with its possibility of high reward.
Companies are investing approximately $400-500 million in
researching, developing, and bringing to market new technologies
that will raise people’s standard of living, improve quality of life,
2
reduce suffering, and promote longevity. These companies need to
3
protect their investments from encroachment by their competition.
Since patents provide the strongest form of intellectual property
protection, obtaining such security is playing an ever-increasing role
4
in the business decisions of companies investing in biotechnology.
I.

BUSINESS AND TECHNOLOGICAL REALITIES IN THE WORLD OF
BIOTECHNOLOGY

The beginning of the 21st century marks the dawn of a new era
with a universe of possibilities for researchers in the field of
biotechnology. In large part, the number of avenues open for
1. See Robert Bazell et al., Biotechnology in 2018: How Will Genetic Science and
Technology Change the World?, 21STC, Fall 1998 (stating that biotechnology has become
“synonymous over the years with very high risk and high reward”), at
http://www.columbia.edu/cu/21stC/issue-3.3/forum_all.html.
2. See Biotechnology Industry Organization (BIO), Primer: Genome and Genetic
Research, Patent Protection and 21st Century Medicine 18 (July 12, 2000) (noting the
average industry investment in a drug totals $500 million or more), available at
http://www.bio.org/genomics/primer.html; John K. Borchardt, The Business of
Pharmacogenomics, 4 MOD. DRUG DISCOVERY 35 (July 2001) (estimating an average
investment of $500 million to bring a drug to market), available at
http://pubs.acs.org/subscribe/journals/mdd/v04/i07/html/07borchardt.html;
William A. Haseltine, The Promise of Genomics, in CONVERGENCE, THE BIOTECHNOLOGY
INDUSTRY REPORT 6 (Ernst & Young, LLP, Millennium ed. 2000) [hereinafter
CONVERGENCE] (reporting that the cost of developing a new drug is $400 million),
available at http://www.ey.com/global/vault.nsf/US/Biotech%5F%5FConvergence
%5F%2D%5FFull%5FReport/%24file/O00254.pdf.
3. See BIO, supra note 2, at 28 (emphasizing that while a patent does not
guarantee a profit, it does prevent competitors from copying the patent holder’s
development and undercutting the potential price of the innovation).
4. See Charles Craig, Current Public Policy Challenges, in CONVERGENCE, supra note
2, at 65 (“Without patents . . . there would be no biotech industry and no innovative
drug development.”); see also IP—The Prize in the Attic, LEGAL TIMES, June 11, 2001, at
18 (noting how companies are coming to recognize their intellectual property as an
“important and relatively untapped asset”).
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exploration is due to significant breakthroughs in methodologies in
5
the gene and protein based areas of pharmaceutical chemistry.
6
During the 20th century, the scientific method was the controlling
modality in innovation. Specifically, scientists first recognized a
problem, developed an approach to study the problem, and then
worked to create specific and particular modes of dealing with the
7
problem. For example, in disease treatments, the first step was to
understand the underlying defect associated with the condition
8
under consideration. This step involved both biochemical and
genetic analysis—determining the biochemical defect and
physiological consequence of this defect and what, if any, genetic
9
basis correlates to the defect. Scientific inquiry started with a
defined endpoint—the treatment or diagnosis of a particular disease
10
In recent years, however, this approach has been
or condition.
supplemented by a less directed approach that has been made
possible by advances in computing, data collection and visualization
11
tools, and combinatorial technologies.
5. See Georg C. Terstappen & Angelo Reggiani, In Silico Research in Drug
Discovery, 22 TRENDS IN PHARMACOLOGICAL SCIENCES 23, 23 (2001) (reflecting that the
introduction of genomic sciences has rendered biology the “main driver” in the
discovery of novel drugs, even in comparison to chemistry and pharmacology). Drug
discovery programs often integrate genomics, protein sciences, and high throughput
screening to identify compounds that show promise of therapeutic application. See
Eliot H. Ohlstein et al., Drug Discovery in the Next Millenium, 40 ANN. REV.
PHARMACOLOGY & TOXICOLOGY 177, 188 fig.3 (2000) (presenting a graphic
representation of the drug discovery progression from molecular targets to novel
therapeutics); see also James A. Landro et al., HTS in the New Millennium: The Role of
Pharmacology and Flexibility, 44 J. PHARMACOLOGICAL & TOXICOLOGICAL METHODS 273,
273 (2000) (discussing the several aspects of discovery: “target identification
(genomics and molecular biology groups); reagent preparation (protein expression
and purification groups); and compound management, assay development, and high
throughput library screening (lead discovery groups)”).
6. See generally The Scientific Method—Elegant Experiments, ACCESS EXCELLENCE @
THE NATIONAL HEALTH MUSEUM (1999) [hereinafter Scientific Method] (stating that
the scientific method is founded on the principles of cause and effect), available at
http://www.accessexcellence.org/AB/BC/ Elegant_Experiments.html.
7. See id.
8. See, e.g., Paul Berg, Reverse Genetics: Its Origins and Prospects, 9 BIOTECH. 342,
343 (Apr. 1991) (describing the classical genetics approach as proceeding “from the
phenotype (disease) to identifying the responsible gene’s chromosomal locus, then
to recovering the gene, and finally to discovering the mutational alteration that
accounts for the disease”).
9. See NATIONAL HUMAN GENOME RESEARCH INSTITUTE FACTSHEET: DISEASE GENE
DISCOVERY 1 (Oct. 1997) (recalling that in the past “scientists needed some idea of
the biochemical errors of a disease before they could search for its genetic basis”),
available at http://www.nhgri.nih.gov/Policy_and_public_affairs/Communications/
Fact_sheets/Disease_gene_discovery.pdf.
10. See, e.g., Scientific Method, supra note 6 (explaining that scientists searched for
and discovered the cause of AIDS before searching for a remedy).
11. See generally Jeffrey Hanke, Genomics and New Technologies as Catalysts for Change
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For example, the science of combinatorial chemistry allows the
generation of complex libraries of chemical compounds that can be
simultaneously assayed, to screen for target molecules that exhibit
12
properties of interest.
Some of these libraries are based upon
particular core structures to which a myriad of substitutions are
made, while in others, many different core structures along with their
13
derivatives are combined. The selection of which cores and what
substitutions are made is often determined by a desire to affect a
particular biological function and to test promising chemical
14
analogues. In other circumstances, the libraries are prepared with
15
no particular target or activity in mind.
In nucleic acid sequencing, as recently as twenty years ago it might
have taken a scientist months to sequence a particular genomic or
16
17
In recent years such sequencing has been
cDNA molecule.
18
automated using banks of highly sophisticated computers allowing
on the order of millions of bases of a nucleic acid sequence to be
19
determined in a single day. The principal limitations today are the
in the Drug Discovery Paradigm, 28 J.L. MED. & ETHICS 15 (2000) (presenting an
overview of new technologies in the fields of informatics, molecular biology,
combinatorial chemistry, and high throughput screening that offer new means to
process the mass of information emerging from genomic sequencing and translate it
into tangible treatments for human diseases).
12. See Stu Borman, Combinatorial Chemistry: Industry is Embracing the Technology
‘Totally,’ as Researchers Continue to Advance the Art of Rapid Synthesis and Screening,
CHEMICAL & ENGINEERING NEWS, Apr. 6, 1998 (discussing how almost all
pharmaceutical companies have embraced this innovation within the last ten years),
available at http://pubs.acs.org/hotartcl/cenear/980406/comb.html.
13. See id. (discussing how pharmaceutical companies create their libraries).
14. See, e.g., Stu Borman, Reducing Time to Drug Discovery, CHEMICAL &
ENGINEERING NEWS, Mar. 8, 1999 (describing a combinatorial research project that
identified non-peptide agonists for each of five different somatostatin receptor types
by starting with small molecules similar in structure to a somatostatin agonist and
then using the compound with the highest binding affinity as a template for library
available
at
construction),
http://pubs.acs.org/hotartcl/cenear/990308/
comb1.html.
15. See Borman, supra note 12, for an overview of several techniques for
producing combinatorial libraries.
16. “cDNA” is complementary deoxyribonucleic acid.
17. See Edward N. Trifonov, Earliest Pages of Bioinformatics, 16 BIOINFORMATICS 5, 6
(2000) (discussing the first painstaking sequencing efforts, which involved the
application of chemical, enzymatic, and spectral analysis techniques to every single
base step, and the breakthrough of “read-the-gel” techniques, which allowed for the
sequencing of 200 nucleotides in a month).
18. Significant improvements in technologies related to genome analysis include
automated sample handling systems, instrumentation for high throughput
sequencing, and more efficient computational tools for analysis of sequence data. See
Fredrik Sterky & Joakim Lundeberg, Sequence Analysis of Genes and Genomes, 76 J.
BIOTECH. 1 (2000) (providing an overview of advances in sequencing methods and
strategies).
19. See, e.g., Elkin, C.J. et al., Abstract, High-Throughput Plasmid Purification for
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amount of physical and financial resources that can be applied to
obtaining raw sequence data and analyzing the data to properly
20
annotate and characterize it.
Whether discussing combinatorial chemistry or nucleic acid
sequencing, the end result is the same—the generation of a large
number of compounds or databases that theoretically would be
21
useful in some context. The question, of course, is in what context?
Medical texts list hundreds of diseases that have both biochemical
22
and genetic bases. Medicine’s goal is to elaborate diagnostics and
treatments. With the advent of large numbers of combinatorial
libraries, it is probable that useful pharmacological agents have been
23
made. The difficulty is in determining which ones they are and
24
what they do. An enormous pool of information has been created,
25
but establishing links between genes and disease will take decades.
26
27
One difficulty in the fields of genomics and proteomics is
Capillary Sequencing, 11 GENOME RESEARCH 1269 (2001) (stating that the Joint
Genome Institute has reached an average throughput of 18.3 million bases per day);
Researchers Unravel Genome for ‘Superbug’ Bacterium Using One Day’s Production Capacity,
LAWRENCE LIVERMORE NATIONAL LABORATORY (May 8, 2000) (heralding that scientists
sequenced 2.8 million base pairs of DNA of the genome of E. faecium using a single
day’s production capacity at the Department of Energy’s Joint Genome Institute’s
Sequencing Facility), available at http://www.llnl.gov/llnl/06news/NewsReleases/
2000/NR-00-05-02.html.
20. See Press Release, European Molecular Biology Laboratory/Sanger Centre,
Taking the Next Step with the Human Genome: Wellcome Trust Announces Major
Investment in Genome Bioinformatics (July 20, 2000) (discussing the center’s new
database for the human genome that was created to address the need for physical
available
at
resources),
http://www.EMBL-Heidelberg.DE/ExternalInfo/
oipa/article1. pdf. For an overview of a number of tools available to help analyze the
sequence data, see David J. Galas, Sequence Interpretation: Making Sense of the Sequence,
291 SCI. 1257 (Feb. 16, 2001), available at http://www.sciencemag.org/cgi/content/
full/291/5507/1257.
21. See, e.g., Hanke, supra note 11, at 15 (discussing how combinational chemistry
or nucleic acid sequencing can potentially help doctors identify a gene mutation
before the onset of a disease).
22. See, e.g., CECIL TEXTBOOK OF MEDICINE (Wyngaarden, J.G. & Smith, L.H. eds.,
1988).
23. See Borman, supra note 12 (noting the progress pharmaceutical companies
are making in developing these libraries).
24. See Ohlstein et al., supra note 5, at 177-91 (“The sheer volume of genetic
information being produced has shifted the emphasis from the generation of novel
DNA sequences to the determination of which of these many new targets offer the
greatest opportunity for drug discovery.”).
25. See Disease Gene Pairing Points to Future, BBC NEWS (Sept. 21, 2001)
(emphasizing the difficulty in finding the causes of diseases that are linked to as
many as six or more mutated genes working together), available at
http://news.bbc.co.uk/hi/english/health/newsid_ 1555000/1555117.stm.
26. See PHARMACEUTICAL RESEARCH AND MANUFACTURERS ASSOCIATION OF
AMERICA’S GENOMICS LEXICON (defining genomics as “the study of genes and their
function”), at http://genomics.phrma.org/lexicon/g.html (last updated Jan. 24,
2002).
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determining which protein is useful for treating what disease, and
28
which gene correlates with what disease. Scientists and companies
require vast sums of money and resources to make those
determinations, but the failure rates in the biotechnology industry
29
are extraordinary. For example, in the pharmaceutical industry, for
every 5,000 to 10,000 compounds screened there are about 250 lead
candidates in pre-clinical testing, and of these, only one is likely to
30
become a Food and Drug Administration (FDA) approved drug. It
may take as long as thirteen years from initial screening to FDA
31
approval, thereby hindering any quick return on investment.
In order to make it worthwhile to expend the time, energy, and
monetary resources necessary for such a research and development
effort, and to counterbalance the significant risk involved in such an
undertaking, products that make it to market must reap significant
profits.
Many companies in the biotechnology industry are
32
supported by venture capital, which is consumed at a high burn
33
rate; long-term investors are needed because it may be a very long
34
time before any return on the initial investment is realized. Thus,
27. See THE BIOSPACE GLOSSARY (defining proteomics as the “study of gene
expression at the protein level, by the identification and characterization of proteins
present in a biological sample”), at http://www.biospace.com/gls_detail.
cfm?t_id=62604 (last visited Jan. 24, 2002). For a description of the basic science
behind genomics and proteomics, see The Science Behind the Human Genome Project,
From the Genome to the Proteome, HUMAN GENOME PROJECT, available at
http://www.ornl.gov/hgmis/ project/info.html (last modified Dec. 7, 2001).
28. See Disease Gene Pairing Points to Future, supra note 25 (discussing the difficulty
of finding the causes of diseases that are linked to as many as six genes working in
combination and therefore developing treatments); see also National Human Genome
Research Institute Factsheet: Disease Gene Discovery, supra note 9, at 2-3 (explaining the
difficulty that scientists face as they move away from studying “single-gene”
disorders).
29. See, e.g., Hanke, supra note 11, at 17 (acknowledging that following up on as
many as 10,000 targets worthy of pursuit for drug discovery will be hugely expensive).
Pharmaceutical companies spend between 1.8 and 4 billion dollars annually on
research and development, yet only one in 100 discoveries yields a product. See id.
30. See The Product Pipeline: Progress and Potential in CONVERGENCE, supra note 2, at
47 (providing a graphic representation).
31. See id. at 46 (discussing the lengthy process of drug approval within the
pharmaceutical industry).
32. See Paula Park, Climbing the Money Tree, THE SCIENTIST, Nov. 26, 2001 (stating
that venture capitalists invested about $260 million per quarter in 2001; $358 million
per quarter in 2000; $144 million per quarter in 1999), available at http://www.thescientist.com/yr2001/nov/prof2_011126.html; see also App. 1, in CONVERGENCE, supra
note 2, at 74 (noting that from July 1998 to June 2000, venture stage financing in the
biotechnology industry totaled $3.1 billion).
33. The burn rate is the amount of money necessary for product research and
development. See Peg Brickley, The ‘Uncompany’ Answer to Building a Company, THE
SCIENTIST, Aug. 20, 2001, available at http://www.thescientist.com/yr2001/
aug/prof2_010820.html.
34. See Nadia S. Halim, Investing in the Future: Innovative Technologies, THE
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companies need to leverage technological innovation to garner
35
In order to raise the necessary funds,
sustaining investments.
companies need to be as forward thinking as possible during the
36
research and development phase. As a result, start up companies
find it critically important to obtain intellectual property rights to
their technological innovations to boost interest from the investment
community and thereby attract the sustaining capital required for
37
their survival. Patents attract the necessary venture capital for these
38
highly entrepreneurial companies to bring their dreams to reality.
Companies in biotechnology related industries are accustomed to
taking business risks, but should they be taking comparable risks on
the legal side in the search for intellectual property protection? A
fine balance exists between obtaining the maximum protection
afforded and crossing over the invalidity line. A patent must be both
39
40
a sword and a shield.
Effective patent protection wards off
SCIENTIST, Aug. 30, 1999, available at http://www.thescientist.com/yr1999/august/
halim_p8_990830.html. While venture capitalists typically look for a two-to-four year
period for a return on investments, biotech investments may require three times
longer to yield any return, thus long-term investors are necessary. See id.
35. For a general discussion of converging technology platforms (e.g.,
information technology approaches applied to biochemistry) and converging market
strategies in the biotechnology industry, see Brian Sager, Strategic Drivers of Converge,
in CONVERGENCE, supra note 2, at 26. Recently, biotechnology companies have
converged with high technology companies in order to capitalize on those nonbiotechnological innovations, thereby creating a hybrid marketplace that builds
upon the industries’ technology, strategies, and business plans. See id. See also
Convergence: A Technology Explosion, in CONVERGENCE, supra note 2, at 17 (commenting
on the growing shift in the biotechnology industry away from the unified research
and development model, toward “a matrix of supply chain relationships along the
drug discovery process, with increasing reliance on technology alliances and
partnerships” (quoting Alex To, Head of Biotechnology Research Group, Credit
Suisse First Boston)).
36. See Peg Brickley, Protecting Intellectual Property, THE SCIENTIST, Oct. 29, 2001
(advising that researchers should contact a patent lawyer before the invention is even
finished), available at http://www.the-scientist.com/yr2001/oct/prof2_011029.html.
37. Rebecca Eisenberg, Patenting Research Tools and the Law, in INTELLECTUAL
PROPERTY RIGHTS AND RESEARCH TOOLS IN MOLECULAR BIOLOGY 6 (Nat’l Academy
Press 1997) [hereinafter Patenting Research Tools] (seeking, for example, patents on
inventions long before those inventions are incorporated into marketable products),
available at http://stills.nap.edu/ html/property/2.html#chap2. Note that while
young firms need patents to recruit investors, established firms seek patents so that
they may dominate a market and raise the money necessary for clinical testing. See
id.
38. See Park, supra note 32 (reviewing the annual venture capital investment in
the pharmaceutical industry).
39. A patent is used as a sword when the patent owner asserts the right to exclude
others from making, using, selling, offering for sale, or importing into the United
States the patented invention. See 35 U.S.C. § 154(a)(1) (2001) (“Every patent shall
contain . . . a grant to the patentee . . . of the right to exclude others from making,
using, offering for sale, or selling the invention . . . ”).
40. A patent functions as a shield by disclosing the patentee’s invention to the
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competitors from invading a company’s space in the marketplace
while helping to defend one’s freedom to operate against
41
competitors’ challenges. Competitors may seek to undermine the
patent because it serves as a tollgate preventing others from acting
42
freely in the market place. Thus patents play a crucial role in the
world of biotechnology.
II. REACH-THROUGH PATENT CLAIMS
The central purpose of the intellectual property system is set forth
in the U.S. Constitution. Article I, Section 8, clause 8 gives the
Congress power to “promote the Progress of Science and useful Arts,
by securing for limited Times to Authors and Inventors the exclusive
Right to their Respective Writings and Discoveries.”
The Founding Fathers of this nation felt strongly that rewarding
innovation in exchange for public disclosures would make the
43
country prosper. Each new discovery builds upon the foundation
44
laid by those that came before it. This concept is built into the U.S.
Patent statutes. As stated in 35 U.S.C. § 101: “Whoever invents or
discovers any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof,
may obtain a patent therefor, subject to the conditions and
requirements of this title.”
Courts addressing patent infringement claims often struggle to
determine the appropriate boundary separating a suitable scope of
protection for what has been invented and disclosed to the public
45
from that which an inventor has not yet put into the public domain.

public, thereby preventing a competitor from obtaining a patent on the same subject
matter or an obvious variant thereof. See id. §§ 102-103.
41. See id. § 154 (extending no right to make or use one’s invention, only the
right to exclude others from the invention).
42. See, e.g., Gregory J. Kirsch, Strategies for the Use of Patents by Start-up Internet
Companies 4 (characterizing the patent as a toll), at www.gigalaw.com/articles/
2000/kirsch-2000-07.html (July 2000).
43. See, e.g., Reps. Ed Bryant & Jim McDermott, Patent Integrity Fuels American
Prosperity (arguing that Article I, section 8, clause 8 makes a “simple, straightforward
and unmistakably clear” statement that the Founding Fathers believed that
innovators should benefit from their labors), at http://www.house.gov/bryant/
claritinoped.html (last visited Jan. 21, 2001).
44. See id. (explaining that benefits for inventors provide the incentive to create
new products that benefit everyone).
45. See Markman v. Westview Instruments, Inc., 517 U.S. 370, 388, 38 U.S.P.Q.2d
(BNA) 1461, 1470 (1996) (noting that patent construction is a “special occupation”
that should be handled by judges who, by virtue of “special training and practice,”
are more likely to give a “proper interpretation” to such highly technical patent
claims).
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The determination of this boundary is especially problematic in the
highly unpredictable areas of biotechnology and pharmaceutical
46
chemistry.
This may be particularly troublesome where patents
contain prophetic disclosures while claiming exclusive rights to all
47
uses of the patented item. For example, in biomedical research the
48
discovery of a new cell receptor that controls physiological events in
the human body may lead to the use of the receptor as a therapeutic
agent. The receptor also may result in the future discovery of
compounds such as hormones that activate the receptor or that
inhibit the receptor. Such future discoveries may be made when the
new receptor is used as a screening reagent in assays to identify and
49
purify previously unknown hormones.
In this example, the inventor might claim the new cell receptor as
50
a product because it can be used as a pharmaceutical. However, an
inventor might also try to claim the new cell receptor for use in a
process for making future discoveries, e.g., a tool used in screening
51
assays that detect previously unknown hormones.
There can be
significant differences between the future discoveries or inventions
that incorporate an original invention and those future discoveries or

46. See, e.g., Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362, 1374, 52
U.S.P.Q.2d (BNA) 1129, 1138 (Fed. Cir. 1999) (dismissing a patent infringement
claim in part because the patent did not provide sufficient guidance or specificity to
the public to meet the enablement test). Courts wrestle with the problem that judges,
who rarely have relevant technical backgrounds, are charged with construing patent
claims to complex inventions in highly technical arts. See, e.g., Cybor Corp. v. FAS
Tech. Inc., 138 F.3d 1448, 1454, 46 U.S.P.Q.2d (BNA) 1169, 1173 (Fed. Cir. 1998)
(en banc) (determining the proper standard of review for findings of fact made by
the district court in patent claims and the proper role of extrinsic evidence in
constructing the scope of those claims). In Cybor Corp., the Federal Circuit split over
the proper standard of review for factual findings made by the lower court, with two
judges concurring with the majority and two judges concurring in the judgment
alone. See id. at 1462-81, 46 U.S.P.Q.2d (BNA) at 1179-97; see also Markman, 517 U.S.
at 389, 38 U.S.P.Q.2d (BNA) at 1470 (noting that patent claims have become
increasingly technical due to legal doctrines that have evolved regarding the scope
and form of claims).
47. See, e.g., Enzo Biochem, Inc., 188 F.3d at 1374.
48. A receptor is a site in a cell, often on a membrane, that can combine with
another specific type of molecule to alter the cell’s function. See generally, John C.
Brown, What the Heck is a Receptor? (Jan. 1999) (describing receptors and their
functions in layman’s terms), at http://people.ku.edu/~jbrown/receptor.
49. See Report of the National Institute of Health (NIH) Working Group on Research Tools
(June 4, 1998) (noting the use of reagents as research tools), available at
http://www.nih.gov/news/researchtools/index.htm.
50. See id. (explaining that a firm that has identified a molecule like a receptor is
likely to regard the molecule as an important proprietary discovery).
51. See id. (recognizing that many biotechnology firms see drug targets and assays
developed from new molecules, rather than the molecules themselves, as “end
products”).
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52

inventions that result from using the original invention.
In the
latter situation, it would be more difficult for the upstream researcher
53
to dominate the subsequent work of downstream investigators.
Because of the risks and potential rewards, biotechnology and
pharmaceutical companies have recognized the desirability of staking
out an intellectual property position where they truly have
54
exclusivity. A greater degree of upstream protection implies greater
control over, and reward from, later developments and downstream
55
technologies. It is not uncommon for parties to enter into contracts
and licensing agreements such as material transfer agreements
56
57
(MTAs) or reach-through license agreements (RTLAs) that
include royalty and/or product reach-through terms. For example,
an agreement might specify that the supplier of a new receptor will
provide the receptor to a researcher for use in seeking new hormones
so long as the supplier receives reach-through royalties on any new
58
hormone discovered or invented by the researcher.
In view of the high stakes involved, an increasing number of patent
applicants seek protection for future downstream inventions through
59
the patent statutes by way of “reach-through claims.” Such patent
52. See id. (describing the conflicts between government research organizations,
public and private universities, and private firms over the licensing of new research
tools in the context of biomedical research).
53. See id. (citing, for example, the fears of private firms that universities using
private research tools might then license their independent discoveries to
competitors of the private firms providing the tools).
54. See, e.g., Strategic Alliances: Leveraging the Tools of Drug Discovery, in
CONVERGENCE, supra note 2, at 48 (noting an increasing emphasis on achieving a
later stage of product development prior to partnering, while retaining greater rights
to the value of the end product).
55. See, e.g., Arti K. Rai, Fostering Cumulative Innovation in the Biopharmaceutical
Industry: The Role of Patent and Antitrust, 16 BERKELEY TECH. L.J. 813, 833 (2001)
(explaining that an original innovator has a strategic advantage over a person
improving on the original innovation because of the ability of the original innovator
to block the improver’s secondary patent).
56. See, e.g., Arti Kaur Rai, Regulating Scientific Research: Intellectual Property Rights
and the Norms of Science, 94 NW. U. L. REV. 77, 111 (1999) (noting that “many MTAs
require researchers to assign or license intellectual property rights to discoveries
made in the course of using the research tools”).
57. See, e.g., Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter
Innovation? The Anticommons in Biomedical Research, SCI., May 1, 1998, at 698-99
(discussing the reach-through license agreement as a mechanism for licensing
patents on upstream biomedical research); see also Nicky Androsov, How Far Should
Biotech Patents Extend?, CURRENT DRUG DISCOVERY, Mar. 2001, at 33 (noting the
increased prevalence of reach-through licenses for research tools), available at
http://www.currentdrugdiscovery.com/CDDPDF/ANDROSOV.pdf.
58. See M. Marchione, Foundation Amends Stem Cell Suit, MILWAUKEE J. SENTINEL,
Sept. 25, 2001, at 1G (chronicling a dispute between the parties of one such
agreement concerning stem cell research).
59. “Reach-through claim” in the sense it is used here means a claim to a future
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protection, if held valid, would avoid the need to negotiate reach60
They would greatly strengthen the patentee’s
through rights.
dominance over future discoveries because such patents grant
exclusive rights to the original patent owner by operation of law
61
rather than as a result of negotiation. While some in the patent
field remain skeptical about the survivability of reach-through claims,
many patent practitioners in the biotechnology arts are now waking
up to the implications of protecting future inventions through this
62
63
technique. This phenomenon is growing on a global scale.
III. FUNDAMENTAL LEGAL FRAMEWORK FOR TREATMENT OF REACHTHROUGH PATENT CLAIMS
In this article, the authors approach the question of the
patentability of reach-through claims by applying the statutory
64
65
66
requirements for utility, written description, and enablement.
The purpose of this article is to proffer a map of the geography of the
legal terrain facing those seeking to patent reach-through claims.
The article defines the requirements that need to be met and
suggests how to meet those requirements. It explores the obstacles
one must face and explains the patentability criteria that must be
invention based on a currently disclosed invention.
60. See Patenting Research Tools, supra note 37 (noting the limited success of reachthrough royalty licensing).
61. See Peter Steele, ‘Mainly on Patents’—an Adventure in Reach-Through, CURRENT
DRUG DISCOVERY, Mar. 2001, at 36-37 (noting that it is easiest to demand royalties for
access to both non-commercial technology and sales of the ultimate products
discovered using that technology, if the patent itself has reach-through claims),
available at http://www.currentdrugdiscovery.com/CDDPDF/STEELE.pdf.
62. See id. at 37 (noting the increasing use of reach-through claims in
applications); see also Trilateral Project B3b, Mutual Understanding in Search and
Examination, Report on Comparative Study on Biotechnology Patent Practices, Theme:
Comparative Study on “Reach-Through Claims” 1 (Nov. 2001) [hereinafter Trilateral
Reach-Through Comparative Study], available at
http://www.uspto.gov/web/tws/
B3b_reachthrough.pdf.
63. See Trilateral Reach-Through Comparative Study, supra note 62 (explaining a
need among the USPTO, Japan Patent Office, and European Patent Office to reach
a mutual understanding concerning the examination of reach-through claims in
light of the trend toward such claims).
64. 35 U.S.C. § 101 (2001) (“Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of matter, or any new and useful
improvement thereof, may obtain a patent therefor, subject to the conditions and
requirements of this title.”).
65. Id. § 112, ¶ 1 (“The specification shall contain a written description of the
invention, and of the manner and process of making and using it . . . ”).
66. Id. (“The specification shall contain a written description of the invention . . .
in such full, clear, concise, and exact terms as to enable any person skilled in the art
to which it pertains, or with which it is most nearly connected, to make and use the
same . . . ”).
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satisfied through the mechanism of a case study.
A. Case Study
Determining compliance with the statutory requirements for
patentability cannot be accomplished by applying per se rules. It is
67
always done on a case-by-case basis. Thus, a case study approach is
used to illustrate the legal principles. To begin, consider the
68
following fact pattern in a patent application.
B. Specification and Evidence of Record
An investigator identified the sequences of the bulk of cDNAs
(complementary DNA) characteristic of mRNAs (messenger RNA)
69
within a liver cell. These sequences were collected in a computer
database and compared to sequences known in the prior art. Based
upon this homology analysis, the investigator determined that a
selected novel cDNA sequence (SEQ ID NO: 1) is a member of an
70
art-recognized family of R-receptors.
Neither evidence in the
specification nor in the prior art raises doubts that the cDNA of SEQ
ID NO: 1 is a member of the family of R-receptors.
In discussing the function and utility of the receptor, the patent
application teaches that different R-receptors are important in a wide
variety of distinct physiological processes. However, no particular
biological or biochemical process in which the claimed new Rreceptor is involved is disclosed. The specification does teach that
activation of the claimed receptor induces a cascade of second-

67. See Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 40, 41
U.S.P.Q.2d (BNA) 1865, 1875 (1997) (expecting that the Federal Circuit will refine
its formulation of legal tests on a case-by-case basis); Purdue Pharma L.P. v. Faulding
Inc., 230 F.3d 1320, 1323, 56 U.S.P.Q.2d (BNA) 1481, 1483 (Fed. Cir. 2000)
(explaining that the test for whether the written description requirement has been
met must be assessed on a case-by-case basis).
68. This case study is based on Example 3 of the Trilateral Reach-Through
Comparative Study, supra note 62, at 31-37.
69. See generally Amgen, Inc. v. Chugai Pharm. Co. Ltd., 927 F.2d 1200, 1207-08
n.4, 18 U.S.P.Q.2d (BNA) 1016, 1022 n.4 (Fed. Cir. 1991); In re O’Farrell, 853 F.2d
894, 895-99, 7 U.S.P.Q.2d (BNA) 1673, 1674-77 (Fed. Cir. 1988) (providing a
discussion of recombinant DNA technology).
70. It is beyond the scope of this paper to provide a discussion of when sequence
homology is sufficient to assign a polynucleotide or polypeptide to a particular class
of compounds. For more discussion of the issue, see Trilateral Project B3b, Mutual
Understanding in Search and Examination, Comparative Study on Biotechnology Patent
Practices, Theme: Nucleic Acid Molecule-Related Inventions Whose Functions are Inferred
Based on Homology Search (Nov. 2001) [hereinafter Trilateral Nucleic Acid Homology
Comparative Study], available at http://www.uspto.gov/web/tws/sr-3-b3b_bio_search.
htm.
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71

messenger signals, similar to that of a G-protein coupled receptor.
The specification also specifically describes a method of identifying
or screening for agonists, i.e., compounds that activate the claimed
receptor, wherein the activated state is detected when a cascade of
second-messenger signals occurs. Thus, there is no reason to doubt
that one could use the claimed R-receptor to find agonist activating
72
compounds. In addition, the application discloses three working
examples wherein compounds activating the claimed receptor,
namely compounds X, Y, and Z, were identified using the disclosed
screening procedure.
The application does not provide any
structural information for compounds other than X, Y, or Z or
methods of making compounds other than X, Y, or Z. Compounds
X, Y, and Z do not share any common structure. Finally, although
the claimed R-receptor was expressed in an animal cell, antibodies
that recognize the receptor were not actually produced.
C. Claimed Inventions
Claim 1. An isolated and purified receptor, the sequence of which
consists of SEQ ID NO: 1.
Claim 2. A method of identifying an agonist of the receptor of
claim 1 comprising:
(a) preparing a candidate compound,
(b) contacting a cell which expresses said receptor on its surface
with said candidate compound, and
(c) determining whether said candidate compound activates the
receptor of claim 1, wherein a compound that activates the receptor
of claim 1 is an agonist of said receptor.

71. G protein-coupled receptors (GPCRs) are members of a superfamily of
receptors which consist of a single protein chain that crosses a cell membrane seven
times. Andrew D. Howard et al., Orphan G-Protein-Coupled Receptors and Natural Ligand
Discovery, 22 TRENDS IN PHARMACOLOGICAL SCI. 132 (2001). GPCRs respond to stimuli
as diverse as odorants, light, hormones, and neurotransmitters that selectively
activate intracellular signaling events. Because GPCRs are centrally positioned in the
cell membrane to initiate a cascade of cellular responses by diverse extracellular
stimuli, it is unsurprising that modulation of GPCR function has resulted in the
production of many marketable therapeutic agents. See id. Research indicates that
GPCRs without natural activating ligands (“orphan GPCRs”) may lead to significant
discovery of important new cellular agents. As a result, the process of identifying
ligands or ‘de-orphanizing’ these novel proteins is a growing field and fosters
ongoing, exciting research in human physiology and pharmacology. See id.
72. For an overview of the approach to drug discovery exemplified herein,
involving the identification and characterization of orphan receptors, see Shelagh
Wilson et al., Orphan G-Protein-Coupled Receptors: The Next Generation of Drug Targets?,
125 BRIT. J. PHARMACOLOGY 1387 (1998).
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Claim 3. An isolated and purified receptor agonist identified by the
method of claim 2.
Claim 4. A method for the treatment of disease treatable by the
agonist of claim 3, comprising administering to a host in need
thereof a therapeutically effective amount of the agonist of claim 3.
Claim 5. A method for treating a disease treatable by compound X
comprising administering to a host in need thereof a therapeutically
effective amount of compound X.
Claim 6. A monoclonal antibody that recognizes the receptor of
claim 1.
IV. LEGAL BACKGROUND
A. Statutory Background
To be granted a patent, at least the following criteria must be met:
subject matter eligibility and utility (35 U.S.C. § 101), written
description (35 U.S.C. § 112, ¶ 1), enablement (35 U.S.C. § 112, ¶ 1),
clarity (35 U.S.C. § 112, ¶ 2), novelty and no loss of rights (35 U.S.C.
§ 102), and non-obviousness (35 U.S.C. § 103). For those applicants
seeking to protect reach-through claims, issues pertaining to lack of
73
utility, enablement, and written description are most likely to arise.
Satisfying these criteria may be the greatest challenge for such
applicants.
1.

Utility
For a subject to be patent eligible, it must be new and useful, and
be encompassed within one of four expansive categories of
74
As recited in 35 U.S.C. § 101: “Whoever invents or
invention.
discovers any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof,
may obtain a patent therefor, subject to the conditions and
73. See, e.g., Trilateral Reach-Through Comparative Study, supra note 62, at 1
(analyzing the Industrial Applicability/Utility (35 U.S.C. § 101 (2001)) and
Enablement/Support/Sufficiency/Written Description and Clarity (35 U.S.C. § 112)
requirements); see also Rai, supra note 55, at 840 (noting the USPTO’s balanced
position on the utility requirement and the Federal Circuit’s rigorous interpretation
of the written description and enablement doctrines in the context of
biotechnology).
74. See Diamond v. Chakrabarty, 447 U.S. 303, 309, 206 U.S.P.Q. (BNA) 193, 197
(1980) (asserting that Congress intended § 101 to “include anything under the sun
that is made by man”); State Street Bank & Trust Co. v. Signature Fin. Group, Inc.,
149 F.3d 1368, 1373, 47 U.S.P.Q.2d (BNA) 1596, 1600 (Fed. Cir. 1998) (reasoning
that Congress’ repeated use of the term “any” in § 101 indicates its expansive
understanding of permissible subject matter).
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requirements of this title.” It is not necessary, however, to dwell on
what category a claimed invention might be pigeon-holed in because
the Federal Circuit has instructed that the primary focus of inquiry
lies not into which category an invention may fall, but rather on
75
whether the claimed invention has practical utility.
76
The statutory requirement that the invention be “useful” has been
interpreted as requiring that a specific and substantial credible utility,
i.e., a practical utility, be available as of the filing date, either as
77
asserted in the specification or as well established in the art.
A “specific utility” refers to the particular claimed subject matter,
unlike a general utility, which covers a broad or collective class of
78
inventions. One must distinguish between applications defining an
invention’s specific use and those indicating an ambiguous or
79
unsubstantiated potential use. For example, a general statement
that a compound has “useful biological” properties and might aid in
the treatment of some unnamed disorders is too vague to qualify as a
80
specific utility. A “substantial utility” should define a “real world”
75. See State Street Bank, 149 F.3d at 1375, 47 U.S.P.Q.2d (BNA) at 1602 (“The
question of whether a claim encompasses statutory subject matter should not focus
on which of the four categories of subject matter a claim is directed to . . . but rather
on the essential characteristics of the subject matter, in particular, its practical
utility.”).
76. Courts have recognized that the term “useful” applied with reference to the
utility requirement can be a difficult term to define. See Brenner v. Manson, 383 U.S.
519, 529, 148 U.S.P.Q. (BNA) 689, 693 (Fed. Cir. 1966) (suggesting that a simple
everyday word like “useful” can be “pregnant with ambiguity when applied
to the facts of life”).
77. See id. at 534-35, 148 U.S.P.Q. (BNA) at 695 (stating that the utility
requirement is not satisfied “unless and until . . .a specific benefit exists in currently
available form”); In re Ziegler, 992 F.2d 1197, 1203, 26 U.S.P.Q.2d (BNA) 1600, 1605
(Fed. Cir. 1993) (explaining that the potential role of an object cannot satisfy the
utility requirement); see also Utility Examination Guidelines, 66 Fed. Reg. 1092, 1098
(Jan. 5, 2001) (recommending that patent applications should be rejected based on
lack of utility if a person of ordinary skill in the art would not consider the asserted
utility specific, substantial, and credible based on all the evidence in the record).
78. See, e.g., U.S. Patent and Trademark Office, MANUAL OF PATENT EXAMINING
PROCEDURE § 2107.01 (8th ed. Aug. 2001) [hereinafter MPEP] (contrasting specific
and general utility), available at http://www.uspto.gov/web/offices/pac/mpep/
mpep.htm.
79. See id. (explaining that applicants must show why and how the invention is
considered useful, not that it may be useful in an unspecified context).
80. See id. (asserting that a general diagnostic utility is insufficient absent an
indication of the specific condition to be diagnosed); see also Kawai v. Metlesics, 480
F.2d 880, 890, 178 U.S.P.Q. (BNA) 158, 165 (C.C.P.A. 1973) (contrasting the
description of an invention as an anticonvulsant, which did suggest specific utility,
with the general suggestion of “pharmacological effects on the central nervous
system” which did not); Application of Kirk, 376 F.2d 936, 941, 153 U.S.P.Q. (BNA) 48,
52 (C.C.P.A. 1967) (holding that an indication that a compound is “biologically
active” or has “biological properties” is insufficient to establish utility); Application of
Joly, 376 F.2d 906, 907-08, 153 U.S.P.Q. (BNA) 45, 46-47 (C.C.P.A. 1967) (explaining
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81

use. If a real world context for using the invention is not reasonably
82
apparent from the record, then the asserted utility is not substantial.
It is inappropriate to label certain types of inventions as incapable
of having a specific and substantial utility based solely on the setting
in which the invention is used, for example, inventions used in a
83
Many research tools used in
research or laboratory setting.
laboratory analysis and the assessment of compounds, such as gas
chromatographs, screening assays, and nucleotide sequencing
techniques, have a clear, specific, and substantial utility in a research
or intermediate context. However this evaluation alone does not
84
focus on the invention’s overall utility in a patent sense. Instead, it
is necessary to distinguish between inventions identifying a present
and specific substantial utility from those requiring additional or
85
future research to establish or verify usefulness. In this process,
applicants’ use of labels like “research tool,” “intermediate,” or “for
research purposes” are not determinative of whether the claimed
86
invention has a specific, substantial and credible utility.
These principles are now applied to the case study, starting with an
analysis of claim 1, set forth supra. The fact pattern indicates that the
claimed receptor is a member of the R-receptor family of proteins.
However, assignment to a family of proteins is generally insufficient
to meet the utility requirement unless such assignment would allow
an artisan to assign a specific and substantial use to the new member
87
of the protein family. In this case, the claimed receptor does not
that the mere disclosure that a compound may lead to the production of future
compounds is insufficient to establish utility).
81. See MPEP, supra note 78, § 2107.01 (explaining the importance of a real
world use).
82. See id. (providing examples of products that require further research and
hence do not constitute substantial utilities); see, e.g., Brenner, 383 U.S. at 534-35, 148
U.S.P.Q. (BNA) at 695 (reasoning that the basic quid pro quo underlying the patent
monopoly requires that the invention be useful in its currently available form).
83. See MPEP, supra note 78, § 2107.01 (resolving the confusion that surrounds
the patentability of research tools).
84. See id.; see also WORKING GROUP ON RESEARCH TOOLS, NAT’L INST. OF HEALTH,
Background: Report of the National Institutes of Health (NIH) (June 4, 1998)
(acknowledging the various perspectives on research tools and listing examples of
such tools), available at http://www.nih.gov/news/researchtools/index.htm.
85. See MPEP, supra note 78, § 2107.01.
86. See id.; see also Patenting Research Tools, supra note 37 (explaining that the
phrase “research tool” is not a term of art in the field of patent law, nor is there any
legal significance in characterizing an invention as a research tool).
87. See generally Trilateral Nucleic Acid Homology Comparative Study, supra note 70
(providing a detailed analysis of the information necessary to satisfy the utility
requirement on the basis of assignment to a family of proteins). Unless each
member of the protein family has the same specific, substantial, and credible utility,
one skilled in the art cannot predict a priori the function of the claimed protein. See
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have a specific utility because the specification does not assert that
the claimed R-receptor has any particular activity nor (on these facts)
would one be readily apparent to a person skilled in the art.
Furthermore, the claimed R-receptor does not have a substantial
utility because further research is necessary to identify the specific use
for the claimed R-receptor. Thus, claim 1 fails to comply with the
utility requirement.
Similarly, claims 2-6, as recited supra, fail to comply with the utility
requirement. Each of the aforementioned claims represents a
prophetic invention downstream from the receptor. If the receptor
does not have a specific, substantial, and credible utility, neither can
any one of the methods of identifying an agonist of the receptor, an
agonist of the receptor, a method of treating a disease treatable by an
agonist of the receptor (where the specific disease to be treated is not
disclosed), or a monoclonal antibody that recognizes the receptor.
It may be possible to overcome a rejection of claims 1-6 for failure
to comply with the utility requirement by presenting objective
evidence that supports the position that one of ordinary skill in the
art would have recognized that each member of the R-receptor
protein family would have been reasonably expected to have a
particular specific and substantial function or activity, or that a
specific and substantial purpose for agonizing such function was
88
known to those of skill in the art.
Alternatively, assume that the fact pattern is changed as follows.
The specification also discloses that the receptor is useful for the
diagnosis of obesity. The relationship between the absence of this
receptor and the occurrence of obesity is determined by
experimental measures of receptor activity, and there is no reason to
doubt that the activation of this receptor can treat or inhibit obesity.
In this situation, claim 1 would meet the utility requirement because
use in diagnostic methods pertaining to obesity is a specific,
substantial, and credible utility. Similarly, methods of identifying an
agonist, the agonist itself, the method of treating obesity with the
agonist, and the monoclonal antibody that recognizes the receptor
would comply with the utility requirement.

id.
88. See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1098 (Jan. 5, 2001)
(discussing the importance of a person of ordinary skill in the relevant art
appreciating the usefulness of the invention).
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2.

Requirements for the specification of a patent application
The specification of a patent application must meet the
requirements set forth in 35 U.S.C. § 112, ¶ 1, which reads:
The specification shall contain a written description of the
invention, and of the manner and process of making and using it,
in such full, clear, concise, and exact terms as to enable any person
skilled in the art to which it pertains, or with which it is most nearly
connected, to make and use the same, and shall set forth the best
mode contemplated by the inventor of carrying out his invention.

This paragraph contains three requirements, usually denominated
as: (1) written description, (2) enablement, and (3) best mode.
3.

Written description
The purpose of the written description requirement is to ensure
that a patent applicant has conveyed to those of skill in the art that
the applicant possessed the invention at the time of filing the patent
89
The written description requirement of 35 U.S.C.
application.
§ 112, ¶ 1, requires that a patent application describe the invention
in such detail that one skilled in the art might reasonably determine
90
that the inventor possessed the invention.
The inventor should
describe the invention’s identifying characteristics to fully define and
91
distinguish the invention. One may demonstrate possession in any
92
of a variety of ways.
In the case of chemical compounds, an applicant must disclose
sufficient identifying characteristics such that those of skill in the art

89. See Vas-Cath v. Mahurkar, 935 F.2d 1555, 1563-64, 19 U.S.P.Q.2d (BNA) 1111,
1117 (Fed. Cir. 1991) (suggesting that the written description serves to do more than
simply explain how to make and use the invention). Compare Enzo Biochem, Inc. v.
Gen-Probe, Inc., 285 F.3d 1013, 1021, 62 U.S.P.Q.2d (BNA) 1289, 1297, (Fed. Cir.
2002) (explaining that possession is a necessary, but not sufficient, condition to
satisfy the written description requirement; applicant must also describe what is
possessed).
90. See Guidelines for Examination of Patent Applications Under the 35 U.S.C.
§ 112, ¶ 1, “Written Description” Requirement, 66 Fed. Reg. 1099, 1014 (Jan. 5,
2001) [hereinafter Written Description Guidelines].
91. See id. (adding that the applicant should employ such descriptive means as
words, structures, figures, diagrams, and formulas to accomplish this); see also
Application of Wertheim, 541 F.2d 257, 262, 191 U.S.P.Q. (BNA) 90, 96 (C.C.P.A.
1976) (“The primary consideration is factual and depends on the nature of the
invention and the amount of knowledge imparted to those skilled in the art by the
disclosure.”).
92. See Written Description Guidelines, supra note 90 (listing possible ways to
show possession including: demonstrating a reduction to practice, showing the
invention was complete and ready for patenting, and describing the invention in
sufficient detail).
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93

can recognize that the applicant possessed the compound. When
the name of a compound, or an invocation of the compound’s
function, is insufficient to identify the compound, further description
94
is needed.
Such disclosure might include descriptions of the
structure, disclosure of the physical and/or chemical properties, the
95
means of making the invention, and functional characteristics.
Functional characteristics may be disclosed by themselves or with
some description of the correlation between the structure and
96
function. For example, if a strong correlation between structure
and function has been accepted in a field of art, one skilled in that
art would be able to confidently predict the invention’s structure
97
from a detailed description of its function. If there is an accepted
correlation between structure and function, the written description
requirement may be satisfied through disclosure of function and
98
minimal structure.
In the absence of such a correlation, an
invention’s structure likely will not be inferred from a mere recitation
99
Without a well-established
of function and minimal structure.
correlation, disclosure of function alone is little more than a hunting
100
license and fails to meet the written description requirement.
93. See, e.g., Fiers v. Revel, 984 F.2d 1164, 1170, 25 U.S.P.Q.2d (BNA) 1601, 1606
(Fed. Cir. 1993) (applying the test of demonstrating possession to a dispute involving
the DNA sequence encoding a protein).
94. For a biomolecule, such as a nucleic acid or a protein, a purely functional
description may be inadequate. See id. (“Claiming all DNA’s that achieve a result
without defining what means will do so is not in compliance with the description
requirement; it is an attempt to preempt the future before it has arrived.”); see also
Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1568, 43 U.S.P.Q.2d
(BNA) 1398, 1406 (Fed. Cir. 1997) (asserting, in the context of genes, that a
definition by function indicates what the invention does, not what it is, and so does
not satisfy the written description requirement); Amgen Inc. v. Chugai Pharm. Co.,
927 F.2d 1200, 1206, 18 U.S.P.Q.2d (BNA) 1016, 1021 (Fed. Cir. 1991) (stating that it
is insufficient to define a chemical compound solely by its principal biological
property, because without further specificity, that is merely “a wish to know the
identity of any material with that biological property”).
95. See Written Description Guidelines, supra note 90, at 1106 (listing factors to
be considered in applying the written description test).
96. See id.
97. See id. at 1110 n.49; see also Purdue Pharma L.P. v. Faulding, Inc., 230 F.3d
1320, 1323, 56 U.S.P.Q.2d (BNA) 1481, 1483 (Fed. Cir. 2000) (requiring that “one
skilled in the art, reading the original disclosure, must immediately discern the
limitation at issue in the claims”).
98. See Written Description Guidelines, supra note 90, at 1110 n.49.
99. See id.
100. See id.; see also Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559,
1568, 43 U.S.P.Q.2d (BNA) 1398, 1406 (Fed. Cir. 1997) (asserting that the written
description requirement is not satisfied by merely providing “a result that one might
achieve if one made that invention”); In re Wilder, 736 F.2d 1516, 1521, 222
U.S.P.Q.(BNA) 369, 372-73 (Fed. Cir. 1984) (affirming a rejection for lack of written
description where the specification merely outlined the goals the inventors sought to
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Applying these principles to the case study, it is apparent that claim
1, directed to an isolated and purified receptor whose sequence is
specifically identified, complies with the written description
101
requirement.
The scope of the claim is limited to a protein
molecule whose primary structure is specifically disclosed.
Claim 2 is directed to a method of identifying agonist compounds.
The specification teaches and exemplifies methods of screening for
compounds that activate the claimed receptor. That is, the activated
state can be detected when a cascade of second-messenger signals
occurs. Based on these facts, one skilled in the art would recognize
that the inventor possessed the claimed method since the specific
102
steps are disclosed.
Claim 3 encompasses agonists identified by the method of claim
103
2. The claimed invention is drawn to a genus of agonist(s)
identified by the method of claim 2 and the specification discloses
three specific compounds within the scope of what is claimed.
However, there is no evidence that there is any recognized
structure/function relationship between the disclosed agonist
compounds and any others that might be found using the claimed
104
method.
Structural identifying characteristics of the genus
members are not disclosed, nor is there a description of other
identifying characteristics sufficient to describe the claimed invention
in such full, clear, concise, and exact terms that a skilled artisan
achieve). But see Fonar Corp. v. Gen. Elec., Co., 107 F.3d 1543, 1549, 41 U.S.P.Q.2d
(BNA) 1801, 1805 (Fed. Cir. 1997) (finding, in the context of software, that
disclosure of the function was adequate in that art).
101. The recitation of the complete amino acid sequence provides the entire
description of the protein’s primary structure. See, e.g., Fiers v. Revel, 984 F.2d 1164,
1172, 25 U.S.P.Q.2d (BNA) 1601, 1607 (Fed. Cir. 1993) (holding that an application
that sets forth a DNA’s “complete and correct nucleotide sequence” meets the
description requirement).
102. See In re Alton, 76 F.3d 1168, 1175, 37 U.S.P.Q.2d (BNA) 1578, 1584 (Fed.
Cir. 1996) (noting that the artisan may reasonably conclude that the inventor
possessed the invention, even if the specification does not explicitly set forth every
nuance of the claims).
103. Claim 2 is drawn to a process of identifying compounds, but it does not
provide patent protection for compounds identified by the process. "A claim covers
and secures a process, a machine, a manufacture, a composition of matter, or a
design, but never the function or result of either, nor the scientific explanation of
their operation." Markman v. Westview Instruments, Inc., 517 U.S. 370, 373, 38
U.S.P.Q.2d (BNA) 1461, 1463 (1996), quoting 6 Lipscomb 21:17, at 315-16
(emphasis added). Thus, even if claim 2 passed the statutory requirements, claim 3
must be examined for its own support in the disclosure as well as for novelty and
nonobviousness.
104. See Regents of the Univ. of Cal., 119 F.3d at 1568, 43 U.S.P.Q.2d (BNA) at 1406
(noting that a definition by function does not satisfy the written description
requirement).
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would recognize that the applicant was in possession of the claimed
invention. Therefore, no written description supports the claimed
invention.
This rejection of claim 3 might be overcome by showing objective
evidence that supports the proposition that the particularly disclosed
receptor agonists were representative of the structure of the group of
molecules that would be detected or identified by the claimed
105
method.
Claim 4, directed to a method for the treatment of disease
treatable by an agonist of the receptor of claim 1, fails to comply with
the written description requirement for the same reasons set forth
with respect to claim 3. Furthermore, the method encompasses
treatment of an unspecified disease, and no evidence indicates that a
treatable disease was known to the applicant. Thus, there is no
disclosure of the actual process steps to be performed when
implementing the invention in the real world. Based upon this fact
pattern, one would conclude that the inventor did not possess the
claimed method of use. In the absence of some understanding of the
disease to be treated, which, if any, agonists could be used to treat
said disease, and how such treatment would be performed, the
artisan would not have accepted that the applicant was in possession
of the claimed method.
Claim 5 fails to meet the written description requirement of 35
U.S.C. § 112, ¶ 1, for the same reasons as set forth above in the
analysis of claim 4, except that compound X itself is adequately
described.
Claim 6 satisfies the written description requirement. The scope of
the claim is limited to an antibody that binds to a particularly recited
106
protein. In view of the manner in which antibodies are made, it is
generally expected that if one is in possession of any particular
protein, one would also have been “in possession,” in the sense
105. See Amgen v. Chugai, 927 F.2d 1200, 1213, 18 U.S.P.Q.2d (BNA) 1016, 1027
(Fed. Cir. 1991) (explaining that an applicant may claim an invention by generically
providing that the description satisfies § 112).
106. See Ailsa M. Campbell, MONOCLONAL ANTIBODY TECHNOLOGY PRODUCTION AND
CHARACTERIZATION OF RODENT AND HUMAN HYBRIDOMAS IN LABORATORY TECHNIQUES at
86 (1985) (“In theory, the immune system of any animal is potentially totipotent.
With a broad enough screening system it should be possible to detect antibodies to
any antigen which has the potential to elicit a response.”); see also In re Wands, 858
F.2d 731, 740, 8 U.S.P.Q.2d (BNA) 1400, 1406 (Fed. Cir. 1988) (reasoning that those
skilled in the monoclonal antibody art could, using the state of the art and
applicant’s written disclosures, produce and screen other hybridomas secreting other
monoclonal antibodies falling within the generic class without undue
experimentation).
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required by the patent law, of the corresponding antibody.
Compliance with the written description requirement does not
require actual reduction to practice of the claimed invention.
4.

Enablement
The enablement requirement appears in 35 U.S.C. § 112, ¶ 1 and
requires that the applicant’s specification provide sufficient
108
disclosure about the invention. A patent specification that provides
only a starting point or direction for further research is not enabling
because it does not provide full and clear terms that teach others how
to make and to use an invention that will be discovered sometime in
109
the future.
As a general principle, the specification must provide enough
instruction so that a person of ordinary skill in the art or technology
would not have to exercise “undue experimentation” to make and to
110
use the invention. Factors that are usually considered in deciding
whether a specification is sufficient include:
(1) The quantity of experimentation necessary, (2) the amount of
direction or guidance presented, (3) the presence or absence of
working examples, (4) the nature of the invention, (5) the state of
the prior art, (6) the relative skill of those in the art, (7) the

107. The Federal Circuit has not addressed this question directly. See Johns
Hopkins Univ. v. Cellpro, Inc., 152 F.3d 1342, 1361, 47 U.S.P.Q.2d (BNA) 1705,
1719 (Fed. Cir. 1998) (relying on Regents of the Univ. of Cal. v. Eli Lilly & Co.,
119 F.3d 1559, 43 U.S.P.Q.2d (BNA) 1398 (Fed. Cir. 1997), CellPro asserted that
claims to an antibody were invalid under the written description requirement. The
court found that Cellpro had not raised the issue below and thus declined to address
it de novo on appeal).
108. 35 U.S.C. § 112 (2001) (mandating that the written description contain “the
manner and process of making and using it, in such full, clear, concise, and exact
terms as to enable any person skilled in the art to which it pertains, or with which it is
most nearly connected, to make and use the same”).
109. See Genentech, Inc. v. Novo Nordisk, 108 F.3d 1361, 1366, 42 U.S.P.Q.2d
(BNA) 1001, 1005 (Fed. Cir. 1997) (clarifying that the patent monopoly is given in
exchange for enabling disclosure, “not for vague intimations of general ideas that
may or may not be workable”); see also Brenner v. Manson, 383 U.S. 519, 536, 148
U.S.P.Q. (BNA) 689, 696 (1966) (“[A] patent is not a hunting license. It is not a
reward for the search, but compensation for its successful conclusion.”).
110. See Enzo Biochem Inc. v. Calgene Inc., 188 F.3d 1362, 1371, 52 U.S.P.Q.2d
(BNA) 1129, 1140 (Fed. Cir. 1999) (explaining that although the necessity of
conducting a reasonable amount of experimentation in order to practice an
invention does not negate compliance with the statutory requirement of
specification, it is critical that the experimentation not be undue); Hybritech, Inc. v.
Monoclonal Antibodies, Inc., 802 F.2d 1367, 1384, 231 U.S.P.Q.2d (BNA) 81, 94
(Fed. Cir. 1986) (stating that the enablement requirement is still satisfied with the
necessity of experimentation, so long as the experimentation is not unduly
extensive).
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predictability
or unpredictability of the art, and (8) the breadth of
111
the claims.

Applying these principles to the case study set forth above, it is
apparent that claim 1, an isolated and purified receptor, complies
112
The
with the “how to make” prong of 35 U.S.C. § 112, ¶ 1.
disclosure of the critical sequence data needed is sufficient, as the
applicant’s disclosure “need not teach, and preferably omits, what is
113
well-known in the art.”
Given the primary protein sequence, the
skilled artisan would have been able to prepare the claimed protein.
However, this claim does not meet the requirement for the “how to
use” prong of 35 U.S.C. § 112, ¶ 1, because the disclosure does not
teach a use that would meet the utility requirement of 35 U.S.C.
114
§ 101.
Claim 2 is directed to a method of identifying an agonist, or
activating compound, of the receptor of claim 1. As a general rule,
the extent of the patent right claimed must have a reasonable
correlation with the extent of the enabled disclosure provided to the
115
public. In this case, the patent application specification includes a
111. See Wands, 858 F.2d at 737, 8 U.S.P.Q.2d (BNA) at 1404; see, e.g., Enzo Biochem.
Inc., 188 F.3d at 1370-75, 52 U.S.P.Q.2d (BNA) at 1135-39 (concluding, through use
of the Wands factors, that the genetic antisense technology application did not meet
the enablement requirement because it was too broad and encompassing, highly
unpredictable, unable to be created by those skilled in antisense technology, and
lacking in directions and working examples).
112. It is assumed that at the time the example application was filed, one of
ordinary skill in the art, working with the sequence data provided by the applicant,
could have synthesized the protein with the ordinary chemical means available at the
time or could have expressed the protein using the genetic engineering means
available at the time.
113. Hybritech, Inc., 802 F.2d at 1384, 231 U.S.P.Q. (BNA) at 94. Courts imply that
it is not necessary to explain every detail, since the inventor is speaking to persons of
ordinary skill in the art. See, e.g., Wands, 858 F.2d at 737, 8 U.S.P.Q.2d (BNA) at 1404
(finding the deposit of living materials in cell depositories necessary and sufficient to
satisfy the enablement requirement of the statute).
114. A strong correlation exists between the “how to use” prong of the
enablement requirement in 35 U.S.C. § 112, ¶ 1 and the requirement for a
disclosure of practical utility found in 35 U.S.C. § 101. See Process Control Corp. v.
HydReclaim Corp., 190 F.3d 1350, 1358, 52 U.S.P.Q.2d (BNA) 1029, 1034-35 (Fed.
Cir. 1999) (“If a patent claim fails to meet the utility requirement because it is not
useful or operative, then it also fails to meet the how-to-use aspect of the enablement
requirement.”); In re Brana, 51 F.3d 1560, 1569, 34 U.S.P.Q.2d (BNA) 1437, 1443
(Fed. Cir. 1995) (classifying practical utility as an implicit requirement of the
enablement provision); Brooktree Corp. v. Advanced Micro Devices, Inc., 977 F.2d
1555, 1571, 24 U.S.P.Q.2d (BNA) 1401, 1412 (Fed. Cir. 1992) (clarifying that if the
subject matter of a patent is inoperable, then the patent may fail to meet both the
utility requirement and the enablement requirement).
115. See In re Fisher, 427 F.2d 833, 839, 166 U.S.P.Q. (BNA) 18, 24 (C.C.P.A 1970)
(prescribing this correlation); see, e.g., In re Vaeck, 947 F.2d 488, 495, 20 U.S.P.Q.2d
(BNA) 1438, 1444 (Fed. Cir. 1991) (finding a lack of correlation between the narrow
disclosure by appellants of certain cyanobacterial genera and the broad degree of
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general description of a series of screening procedures
commensurate in scope with those recited in the claims. Considering
the level of skill and knowledge in the art, one skilled in the art would
be able to practice the first two process steps of claim 2 (preparing a
candidate compound and contacting a cell that expresses the
receptor with the candidate compound) because the receptor is
enabled. One skilled in the art would be able to practice the third
step (determining whether the candidate compound activates the
receptor) because the specification teaches that the activated state
can be detected when a cascade of second-messenger signals occurs.
Thus the claim meets the “how to make” prong of 35 U.S.C. § 112,
¶ 1. However, claim 2 fails to meet the “how to use” requirement of
35 U.S.C. § 112, ¶ 1, for reasons set forth above in the analysis of the
compliance of the claimed invention with the requirements of 35
U.S.C. § 101.
Claim 3 is directed to an isolated and purified receptor agonist
identified by the method of claim 2. The issue of extrapolating
results from one compound to other more or less similar compounds
arises frequently in pharmacology and biotechnology. Thus, courts
generally decide on a case-by-case basis whether those of skill in the
art would accept results obtained with tested compounds as sufficient
116
to support an inference of activity for an untested compound.
In
this case, the specification discloses three compounds that fall within
the scope of the claim. However, the instructions do not detail how
to make agonists other than X, Y, and Z. No factors indicate that X,
Y, and Z are a representative number of structurally related
compounds such that they constitute full, clear, and concise
instructions for making other agonists. Courts generally require a
117
full range of disclosure pertaining to the operation of the claim.

protection the appellants wanted to obtain for the gene expression of all
cyanobacteria).
116. See, e.g., Brenner v. Manson, 383 U.S. 519, 531-32, 148 U.S.P.Q. (BNA) 689,
694 (1966) (finding that, despite the reference in the respondent’s application to an
adjacent homologue, the respondent failed to present a sufficient likelihood that his
process would result in a steroid with similar tumor-inhibiting characteristics); see also
Brana, 51 F.3d at 1567, 34 U.S.P.Q.2d (BNA) at 1442 (noting that “evidence of
success with structurally similar compounds is relevant in determining whether one
skilled in the art would believe an asserted utility”).
117. See PPG Indus., Inc. v. Guardian Indus. Corp., 75 F.3d 1558, 1564, 37
U.S.P.Q.2d (BNA) 1618, 1623 (Fed. Cir. 1996) (“In unpredictable art areas, this
court has refused to find broad generic claims enabled by specifications that
demonstrate the enablement of only one or a few embodiments and do not
demonstrate with reasonable specificity how to make and use other potential
embodiments across the full scope of the claim.”).
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One skilled in the art would not know the identity of any nondisclosed compound falling within the scope of the claim and
consequently would not be able to make it. An assay for finding a
118
product is not equivalent to a method for making that product.
Therefore, claim 3 fails to meet the enablement requirement for the
“how to make” prong of 35 U.S.C. § 112, ¶ 1.
Similarly, and for reasons set forth above in the analysis of the
compliance of the claimed invention with the requirements of 35
U.S.C. § 101, the claimed agonist fails to meet the requirements of
the “how to use” prong of 35 U.S.C. § 112, ¶ 1.
Claim 4 is directed to treating a disease with an agonist of the
receptor set forth in claim 1. As noted above, the enablement
requirement mandates that the specification allows artisans to make
119
and to use the invention without undue experimentation.
In the
instant case, no treatable disease is disclosed in the specification, nor
is there any information as to how any particular undisclosed agonist
would have been administered to treat any specific disease. In view of
these facts, the artisan would not have been able to make the claimed
invention without undue experimentation. Similarly, and for reasons
set forth above in the analysis of the compliance of the claimed

118. A claim to the process of claim 2 would not "cover" compounds identified by
the process. See Markman v. Westview Instruments, Inc., 517 U.S. 370, 373, 38
U.S.P.Q.2d (BNA) 1461, 1463; see also Bayer AG v. Housey Pharm., Inc., 169 F. Supp.
2d 328, 330, 61 U.S.P.Q.2d (BNA) 1051, 1053 (D. Del. 2001) (holding that while it is
an act of infringement to import into the United States, or offer to sell, sell, or use
within the United States, a product which is made by a process patented in the
United States pursuant to 35 U.S.C. § 271(g), that section “addresses only products
derived from patented manufacturing processes, i.e., methods of actually making or
creating a product as opposed to methods of gathering information about, or
identifying, a substance worthy of further development")(emphasis in original).
There are situations where a product composition can be defined by the process of
making the compound. Where the transformation of an identified starting material
is detailed in one or more process steps, a product-by-process claim can be
appropriate for an otherwise patentable product that resists definition by other than
the process by which it was made. See, e.g., In re Thorpe, 777 F.2d 695, 697, 227
U.S.P.Q. (BNA) 964, 965-66 (Fed. Cir. 1985) (explaining that novelty and
nonobviousness of the product are not assured by the novelty or nonobviousness of
the process). However, the process of claim 2 does not have any steps that produce a
new product by transforming a starting material because claim 2 assays an existing
compound without producing a new compound. The process of claim 2 is accurately
described as a process that uses a starting material. See Mentor Corp. v. Coloplast,
Inc., 998 F.2d 992, 997, 27 U.S.P.Q.2d (BNA) 1521, 1526 (Fed. Cir. 1993)
(distinguishing product-by-process claims from process claims relating to how a
product is used).
119. See Enzo Biochem Inc. v. Calgene Inc., 188 F.3d 1362, 1371, 52 U.S.P.Q.2d
(BNA) 1129, 1140 (Fed. Cir. 1999); Nat’l Recovery Techs., Inc. v. Magnetic
Separation Sys., Inc., 166 F.3d 1190, 1195, 49 U.S.P.Q.2d (BNA) 1671, 1676 (Fed.
Cir. 1999) (discussing the enablement requirement).
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invention with the requirements of 35 U.S.C. § 101, the claimed
method fails to meet the requirements of the “how to use” prong of
35 U.S.C. § 112, ¶ 1.
Claim 5, directed to a method for treating a disease with a specific
agonist compound, fails to meet the requirements of the enablement
requirement of 35 U.S.C. § 112, ¶ 1, for the same reasons as set forth
above in the analysis of claim 4, except that one skilled in the art
would be able to make compound X based on the disclosure.
Claim 6 is directed to a monoclonal antibody that recognizes the
receptor of claim 1. Courts generally find that with claims relating to
chemical matter, generic formulae are sufficiently specific to provide
120
adequate descriptions of the claimed creation. In the instant case,
given the primary protein structure from which an antibody is to be
made, one skilled in the art would be able to use routine and well121
known methods to prepare an antibody to such a target. Therefore
this claim meets the enablement requirement for the “how to make”
prong of 35 U.S.C. § 112, ¶ 1.
However, claim 6 does not meet the requirement for the “how to
use” prong of 35 U.S.C. § 112, ¶ 1, because the disclosure does not
teach a use that would meet the utility requirement of 35 U.S.C.
§ 101.
5.

Best mode
The third requirement of 35 U.S.C. § 112, ¶ 1, is that the
applicant’s specification shall set forth the best mode contemplated
122
123
for carrying out the claimed invention.
by the inventor
Determining compliance with the best mode requirement requires a
120. See Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1568, 43
U.S.P.Q.2d (BNA) 1398, 1406 (Fed. Cir. 1997) (explaining that with claims
pertaining to chemical materials “generic formulae usually indicate with specificity
what the generic claims encompass”).
121. See In re Wands, 858 F.2d 731, 736, 8 U.S.P.Q.2d (BNA) 1400, 1403-04 (Fed.
Cir. 1988) (discussing the relationship between antibodies and antigens).
122. See Eli Lilly & Co. v. Barr Labs. Inc., 251 F.3d 955, 963, 58 U.S.P.Q.2d (BNA)
1869, 1874 (Fed. Cir. 2001) (noting that the best mode requirement is part of the
bargain for exchange contemplated in granting a patent right).
123. See, e.g., id. at 966, 58 U.S.P.Q.2d (BNA) at 1877 (noting that the patentee
need not disclose an “unclaimed preferred mode for accomplishing a routine
detail . . . because one skilled in the art is aware of alternative means for
accomplishing the routine detail that would still produce the best mode of the
claimed invention”); N. Telecom Ltd. v. Samsung Elecs. Co., 215 F.3d 1281, 1288, 55
U.S.P.Q.2d (BNA) 1065, 1070 (Fed. Cir. 2000) (holding that the best mode
requirement was satisfied even though thin-line etching, an unclaimed, preferred
method for the process for gaseous etching of aluminum and aluminum oxides, was
not disclosed in the specification because the claim sufficiently described a general
process of plasma etching and the best mode for carrying out that process).
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124

two-prong factual inquiry. First, a fact-finder must decide whether
an inventor had the best mode for practicing the claimed invention
125
at the time the inventor filed the application.
To make this
determination, the fact-finder must assess the inventor’s state of mind
126
Second, if the inventor did possess a best
at the time of filing.
mode, the fact-finder must determine “whether the written
description disclosed the best mode such that a person skilled in the
127
art could practice it.”
This determination requires an objective
inquiry that focuses on the scope of the claimed invention and the
128
level of skill in the art.
Courts will usually determine if the best
mode requirement is satisfied based upon whether the applicant has
contemplated and subsequently concealed the best mode by not
129
disclosing it. If a claim is truly a reach-through claim, the applicant
may not have set forth any mode or embodiment of the invention
because the discovery or invention has not been made yet. While this
130
is not a best mode issue, it may be an enablement problem.
V. IMPLICATIONS OF FAILURE TO COMPLY WITH 35 U.S.C. §§ 101 AND
112, ¶ 1
The inadequate disclosure problems detailed above could very well
prove to be fatal to the claims in this case study. Applicants cannot
amplify the description by adding later-discovered evidence because
such efforts go beyond the specification as filed and are prohibited as
131
introducing new matter.
New or amended claims that introduce
elements or limitations that are not supported by the disclosure as it
132
is originally filed violate the written description requirement.
124. See Barr Labs. Inc., 251 F.3d at 963, 58 U.S.P.Q.2d (BNA) at 1874 (setting
forth the test).
125. See id.
126. See id.
127. See id.
128. See id.
129. See Chemcast Corp. v. Arco Indus. Corp., 913 F.2d 923, 927-28, 16 U.S.P.Q.2d
(BNA) 1033, 1035 (Fed. Cir. 1990) (articulating the importance of concealment).
130. See Application of Glass, 492 F.2d 1228, 1233, 181 U.S.P.Q. (BNA) 31, 35
(C.C.P.A. 1974) (indicating that in at least some situations “[f]ailure to set forth any
mode . . . equivalent to non-enablement”).
131. See 35 U.S.C. § 132 (2001) (stating that “[n]o amendment shall introduce
new matter into the disclosure of the invention”); id. § 251 (indicating that “[n]o
new matter shall be introduced into the application for reissue” of a defective
patent).
132. See, e.g., Application of Lukach, 442 F.2d 967, 969, 169 U.S.P.Q. (BNA) 795,
796-97 (C.C.P.A. 1971) (determining that the generic disclosure and singular specific
example provided by the previously-filed patent application did not support the
subgenus range at issue); see also Application of Smith, 458 F.2d 1389, 1395, 173
U.S.P.Q. (BNA) 679, 683 (C.C.P.A. 1972) (concluding that a “subgenus is [not]
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While the written description requirement of 35 U.S.C. § 112 does
133
not mandate in haec verba disclosure, it requires that newly added
claim limitations must be supported in the specification through
134
135
136
express, implicit, or inherent disclosure.
Furthermore, it is doubtful that the applicant could overcome
these defects through affidavit or declaration showings under 37
137
C.F.R. § 1.132. After-the-fact submissions cannot make up for what
is required to be in the specification by supplementing the as-filed
application. Affidavits or declarations presented to show that the
disclosure of an application is sufficient to one skilled in the art are
not acceptable to establish facts that the specification itself should
138
recite. Each patent specification filed is required to disclose to the
public how to use an invention. If necessary information is added in
a later filed application that asserts benefit to an earlier application
that is lacking such information, the later filed application is not
entitled to the benefit of the filing date of the earlier filed
139
application.
In some cases, breaks in the continuity of disclosure
necessarily described by a genus encompassing it and a species upon which it
reads”).
133. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1570, 39 U.S.P.Q.2d (BNA)
1895, 1904 (Fed. Cir. 1996) (requiring only that the disclosure in the application
“reasonably convey” to those skilled in the art that the inventor possessed the
disputed subject matter).
134. When an explicit limitation in a claim “is not present in the written
description whose benefit is sought, it must be shown that a person of ordinary skill
would have understood, at the time the patent application was filed, that the
description requires that limitation.” Hyatt v. Boone, 146 F.3d 1348, 1353,
47 U.S.P.Q.2d (BNA) 1128, 1131 (Fed. Cir. 1998).
135. See, e.g., Application of Smith, 458 F.2d at 1395, 173 U.S.P.Q. (BNA) at 683
(noting the lack of an implicit relationship between a subgenus and encompassing
genus).
136. “To establish inherency, the extrinsic evidence must make clear that the
missing descriptive matter is necessarily present in the thing described in the
reference, and that it would be so recognized by persons of ordinary skill.” See In re
Robertson, 169 F.3d 743, 745, 49 U.S.P.Q.2d (BNA) 1949, 1950-51 (Fed. Cir. 1999)
(citations omitted). “Inherency, however, may not be established by probabilities or
possibilities. The mere fact that a certain thing may result from a given set of
circumstances is not sufficient.” Id. (citations omitted).
137. See 37 C.F.R. § 1.132 (2002) (“When any claim of an application or a patent
under reexamination is rejected or objected to, any evidence submitted to traverse
the rejection or objection on a basis not otherwise provided for must be by way of
oath or declaration under this section.”); see generally MPEP, supra note 78, § 716
(providing a detailed discussion of affidavits and objections filed under 37 C.F.R.
§ 1.132).
138. See In re Buchner, 929 F.2d 660, 661, 18 U.S.P.Q.2d (BNA) 1331, 1332 (Fed.
Cir. 1991) (finding the declaration by an expert as to how he would construct
elements necessary to the claimed invention was insufficient either to make up for
the fact that the construction did not appear in the application or the prior art, or to
demonstrate that the construction was well-known to the relevant artisans).
139. See, e.g., Application of Hogan, 559 F.2d 595, 609, 194 U.S.P.Q. (BNA) 527,
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may permit application of intervening references that preclude
140
patentability.
CONCLUSION
When a new receptor is discovered, and its ligands, agonists,
antagonists, or binding partners remain unknown, the receptor
might be used in screening assays to discover the unknown ligands or
to serve other functions. This is not unlike panning for gold. Just as
the seller of a pan for use in panning for gold might like to have a
claim to the gold discovered by operators using the pan, the inventor
of a new receptor might like to have a claim to whatever ligands,
agonists, antagonists or binding partners of the receptor that might
141
be discoverable. If a claim to such compounds is presented in an
application in which the only information about the compounds is
that they remain to be discovered, it is likely that the claim will be
rejected for lack of an adequate written description and lack of an
enabling disclosure.
Reach-through claims are not patentable because they do not
satisfy the requisite disclosure criteria for obtaining a patent, which is
found in the requirements of 35 U.S.C. §§ 101 and 112, ¶ 1. The
reach-through invention does not exist as of the filing date of the
application for patent. By its nature, the inventor cannot describe it
in such terms that one skilled in the art would have recognized that
the inventor had possession of the claimed subject matter, nor can
the inventor provide sufficient teachings of how to make or use the
reach-through invention. Indeed, the inventor cannot provide a
sufficient disclosure so others may know what it is that they are
excluded from making, using, selling, offering for sale, or importing
142
into the United States.
540 (C.C.P.A. 1977) (determining that the failure to disclose a graph in a 1956
patent application that had been disclosed previously in a 1953 application and
subsequently in the 1967 application created a gap in the continuity of disclosure
necessary to secure the benefit of 35 U.S.C. § 120 and resulted in the claim receiving
only the benefit of the 1967 filing date in which it was introduced).
140. See id. at 604, 194 U.S.P.Q. (BNA) at 536 (discussing the effect of intervening
references).
141. Another commentator on reach-through claims captured the essence of
these mechanisms by asking “if I sell you a piano, can I have a royalty on the songs
you write?” Terry Stancliffe, Cantab Pharmaceuticals, quoted in Nicky Androsov, How
Far Should Biotech Patents Extend?, CURRENT DRUG DISCOVERY, Mar. 2001, at 34,
available at http://www.currentdrugdiscovery.com/CDDPDF/ANDROSOV.pdf.
142. Similarly, if an inventor is granted a patent that includes a reach-through
claim, there is some probability that in an enforcement proceeding or infringement
suit, the patent owner may find that, as a true appreciation of what the invention
encompasses evolves, subject matter in the prior art will be found to invalidate the
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Reach-through claims are inconsistent with the purpose of the
patent statutes, which seek to implement ways to “promote the
progress of . . . useful arts,” because they could inhibit the progress of
143
scientific development without compensating the public.
As
gatekeeper for the patent system, the USPTO must take a
conservative approach with respect to determining whether such
claims meet the utility, written description, and enablement
144
requirements. Challenges by the adventuresome in the courts are
expected. The law is dynamic and decisions of the federal courts
and/or legislation enacted by Congress may change the future
landscape and force a new respect for reach-through claims.
Applicants seeking reach-through claims will either have to bear the
burden of convincing the USPTO, and ultimately the courts, that
145
such claims are consistent with the patent laws, or bear the burden
of convincing Congress that statutory changes permitting such claims
are necessary to protect embryonic industries and to allow these
industries to flourish and to deliver the promise of a better tomorrow.

claims under § 102. See 35 U.S.C. § 102 (2001) (setting forth the specification for
novelty and the conditions that can lead to the loss of a patent).
143. See Brenner v. Manson, 383 U.S. 519, 534, 148 U.S.P.Q. (BNA) 689, 695
(1966) (noting this danger of blocking scientific development without
compensation).
144. See Rai, supra note 55, at 841 (concluding that “[w]hile the PTO guidelines
reflect the Federal Circuit’s position, they also respond quite specifically to concerns
lodged both by the National Institutes of Health and the academic research
community about the problems for subsequent researchers created by broad patents
on upstream research”).
145. Prophetic disclosures in biotechnology inventions have generally received a
hostile reception in the Federal Circuit. See Enzo Biochem. Inc. v. Calgene, Inc., 188
F.3d 1362, 1372, 52 U.S.P.Q.2d (BNA) 1129, 1136-37 (Fed. Cir. 1999) (finding that
the high unpredictability in the antisense technology and the extensive nature of
experiments to practice the technology rendered the disputed claims invalid);
Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1567, 43 U.S.P.Q.2d
(BNA) 1398, 1405 (Fed. Cir. 1997) (stating that a written disclosure must allow
skilled experts to practice the invention or method and not just provide a “mere wish
or plan” for practicing the invention in the future); Amgen Inc. v. Chugai Pharm.
Co., 927 F.2d 1200, 1206, 18 U.S.P.Q.2d (BNA) 1016, 1020-21 (Fed. Cir. 1991)
(clarifying that the conception of an invention necessary for the disclosure required
for patents entails then current possession of an operative method for making the
invention).

